Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects.

@article{Schram2004RanolazineIA,
  title={Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects.},
  author={Gernot Schram and Liming Zhang and Katayoun Derakhchan and Joachim R. Ehrlich and Luiz Belardinelli and Stanley Nattel},
  journal={British journal of pharmacology},
  year={2004},
  volume={142 8},
  pages={1300-8}
}
Ranolazine is a novel anti-ischemic drug that prolongs the QT interval. To evaluate the potential mechanisms and consequences, we studied: (i) Ranolazine's effects on HERG and IsK currents in Xenopus oocytes with two-electrode voltage clamp; (ii) effects of ranolazine, compared to d-sotalol, on effective refractory period (ERP), QT interval and ventricular rhythm in a dog model of acquired long QT syndrome; and (iii) effects on selected native currents in canine atrial myocytes with whole-cell… CONTINUE READING